Last reviewed · How we verify
IIA2:3E9 PFU of oncolytic virus, sequentially combination — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
IIA2:3E9 PFU of oncolytic virus, sequentially combination (IIA2:3E9 PFU of oncolytic virus, sequentially combination) — Peking University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| IIA2:3E9 PFU of oncolytic virus, sequentially combination TARGET | IIA2:3E9 PFU of oncolytic virus, sequentially combination | Peking University | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- IIA2:3E9 PFU of oncolytic virus, sequentially combination CI watch — RSS
- IIA2:3E9 PFU of oncolytic virus, sequentially combination CI watch — Atom
- IIA2:3E9 PFU of oncolytic virus, sequentially combination CI watch — JSON
- IIA2:3E9 PFU of oncolytic virus, sequentially combination alone — RSS
Cite this brief
Drug Landscape (2026). IIA2:3E9 PFU of oncolytic virus, sequentially combination — Competitive Intelligence Brief. https://druglandscape.com/ci/iia2-3e9-pfu-of-oncolytic-virus-sequentially-combination. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab